Hydronidone

DRUG4 trials

Sponsors

Shanghai Genomics, Inc., Beijing Continent Pharmaceutical Co, Ltd.

Conditions

Hepatic FibrosisHepatitis B, ChronicHepatitis b & Liver DysfunctionPharmacokinetics of Hydronidone

Phase 1

Study on PK of Hydronidone in Patients and Special Population

CompletedNCT04123769

Beijing Continent Pharmaceutical Co, Ltd.Hepatitis b & Liver Dysfunction

Start: 2019-09-03End: 2021-01-30Updated: 2021-03-24

Study on Pharmacokinetics of Hydronidone

CompletedNCT04162821

Beijing Continent Pharmaceutical Co, Ltd.Pharmacokinetics of Hydronidone

Start: 2019-10-30End: 2021-03-01Updated: 2021-03-24

QTc Assessment in a Single-Dose Study of Hydronidone Capsules

CompletedNCT07263152

Beijing Continent Pharmaceutical Co, Ltd.Hepatic Fibrosis

Start: 2025-12-30End: 2026-02-09Updated: 2026-08-13

Phase 2

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

CompletedNCT02499562

Shanghai Genomics, Inc.Hepatitis B, Chronic

Start: 2015-06-25End: 2020-11-20Updated: 2022-06-23

Related Papers

Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial

Clinical Gastroenterology and Hepatology2022-07-1330 citations